Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Suicide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    362 result(s) found for: Suicide. Displaying page 8 of 19.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2021-005387-22 Sponsor Protocol Number: ACP-103-069 Start Date*: 2022-06-27
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
    Medical condition: Treatment of irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) HU (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004790-31 Sponsor Protocol Number: 55308942BIP2001 Start Date*: 2022-05-31
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression
    Medical condition: Bipolar Depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016064-36 Sponsor Protocol Number: GWCA0958 Start Date*: 2010-03-10
    Sponsor Name:GW Pharma Ltd.
    Full Title: A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in p...
    Medical condition: Pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) BE (Completed) GB (Completed) DE (Completed) RO (Completed) HU (Completed) EE (Prematurely Ended) LV (Completed) LT (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-003288-20 Sponsor Protocol Number: BN29553 Start Date*: 2017-05-07
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) GR (Prematurely Ended) FR (Completed) SE (Prematurely Ended) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003289-15 Sponsor Protocol Number: 0169 Start Date*: 2019-05-08
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled,Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Auton...
    Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) EE (Completed) DE (Completed) DK (Completed) AT (Completed) HU (Completed) PL (Completed) ES (Ongoing) BG (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004431-24 Sponsor Protocol Number: 67896153MSC3001 Start Date*: 2022-11-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Vers...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) SE (Completed) IT (Prematurely Ended) FR (Ongoing) BE (Completed) PL (Completed) CZ (Completed) BG (Completed) HU (Prematurely Ended) PT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000942-21 Sponsor Protocol Number: AIMS-2-CT1 Start Date*: 2019-07-24
    Sponsor Name:Celso Arango
    Full Title: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents w...
    Medical condition: Autism Spectrum Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10003805 Autism LLT
    20.0 10037175 - Psychiatric disorders 10003805 Autism LLT
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002327-29 Sponsor Protocol Number: RGH-188-201 Start Date*: 2017-01-05
    Sponsor Name:Gedeon Richter Plc.
    Full Title: Open-Label, Multicentre, Multiple Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Cariprazine in Adolescent Subjects with Schizophrenia, Schizoaffective- and Schizophreniform Di...
    Medical condition: Schizophrenia, Schizoaffective- and Schizophreniform Disorders
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039620 Schizoaffective and schizophreniform disorders HLT
    20.0 100000004873 10039631 Schizophrenia NEC HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-004799-23 Sponsor Protocol Number: BP39642 Start Date*: 2017-09-04
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE II, SINGLE ARM, MULTICENTER, PROOF OF MECHANISM STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BITOPERTIN (RO4917838) IN ADULTS WITH NON-...
    Medical condition: β-Thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10074356 Non-transfusion dependent thalassemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004513-33 Sponsor Protocol Number: OCTUMI-02 Start Date*: 2008-05-08
    Sponsor Name:University of Oxford
    Full Title: Comparative Evaluation of QUEtiapine-Lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in patients with bipolar depression
    Medical condition: Bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10004936 Bipolar depression LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002557-56 Sponsor Protocol Number: ACT11705 Start Date*: 2011-11-24
    Sponsor Name:sanofi-aventis
    Full Title: A randomized, double-blind, parallel-group, placebo-controlled study to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer pain
    Medical condition: cancer pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10069398 Breakthrough cancer pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001556-21 Sponsor Protocol Number: SEP361-202 Start Date*: 2016-10-27
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000757-13 Sponsor Protocol Number: RGH-MD-54 Start Date*: 2016-06-07
    Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo...
    Medical condition: Bipolar I Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-003972-21 Sponsor Protocol Number: DS5565-A-U307 Start Date*: 2015-09-10
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED SAFETY STUDY OF DS-5565 FOR TREATMENT OF PAIN DUE TO FIBROMYALGIA IN SUBJECTS WITH CHRONIC KIDNEY DISEASE
    Medical condition: DS-5565 is being investigated for the treatment of pain associated with fibromyalgia (FM) in subjects with chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003227-66 Sponsor Protocol Number: BP29937 Start Date*: 2016-09-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, placebo-controlled, parallel group, safety, efficacy and pharmacodynamic study of basmisanil (RO5186582) in adults with severe motor impairment following an ischemic stroke
    Medical condition: Stroke Motor Recovery
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001084-20 Sponsor Protocol Number: TAK-041-2001 Start Date*: 2017-08-16
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects W...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002939-34 Sponsor Protocol Number: GWEP1424 Start Date*: 2014-12-29
    Sponsor Name:GW Research Ltd
    Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
    Medical condition: Dravet syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10073677 Severe myoclonic epilepsy of infancy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000736-33 Sponsor Protocol Number: CAFQ056X2201 Start Date*: 2017-10-25
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A randomized, subject and investigator blinded, placebo-controlled, parallel group study to investigate whether AFQ056 reduces cocaine use in patients diagnosed with Cocaine Use Disorder (CUD).
    Medical condition: Cocaine Use Disorder according to DSM 5
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000173266 10009815 Cocaine addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004079-38 Sponsor Protocol Number: 01112012 Start Date*: 2013-01-14
    Sponsor Name:Central Institute of Mental Health, Department of Psychiatry and Psychotherapy
    Full Title: Agomelatine treatment of major depressive episodes in the course of schizophrenic psychoses (AGOPSYCH). A single arm, prospective pilot study
    Medical condition: Major depressive episode
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002088-98 Sponsor Protocol Number: AN01.01.0012 Start Date*: 2005-11-07
    Sponsor Name:Amarin Neuroscience Ltd
    Full Title: Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease
    Medical condition: HUNTINGTON’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    8.0 10010331 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 17:29:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA